Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pediatric Dermatology · Giant Congenital Melanocytic Nevus

Understanding the Associated Risks: NCM and Melanoma

At a Glance

While most giant congenital melanocytic nevi (GCMN) remain benign, children require long-term monitoring for neurocutaneous melanocytosis (NCM) and melanoma. A proactive plan involving baseline MRIs, deep tissue physical exams, and neurological checkups is essential for managing these risks.

While most Large and Giant Congenital Melanocytic Nevi (LCMN/GCMN) remain benign throughout a person’s life, there are two primary medical risks that require long-term monitoring: Neurocutaneous Melanocytosis (NCM) and Melanoma [1][2]. Understanding these risks helps you and your care team create a proactive monitoring plan.

Neurocutaneous Melanocytosis (NCM)

NCM is a rare condition where the same pigment-producing cells (melanocytes) found in the skin nevus are also present in the brain or spinal cord [3][4]. In most cases, these cells are “silent” and do not cause problems, but they can sometimes grow and interfere with the central nervous system [5].

Risk Factors for NCM

Not every child with a large nevus has the same risk for NCM. Doctors look for specific signs that suggest a higher likelihood of brain or spine involvement [6][7]:

  • Projected Adult Size (PAS) >40 cm: Very large nevi, often called “Giant,” carry the highest risk [7].
  • Satellite Nevi: Having more than 20 smaller “satellite” spots at birth is a significant risk factor [7].
  • Anatomical Location: Nevi located on the “posterior axis”—the head, neck, or anywhere along the spine—are more closely linked to NCM [6][3].

Symptoms to Watch For

If NCM becomes symptomatic, it is often because the extra pigment cells are blocking the flow of fluid in the brain or causing irritation [5]. Signs may include:

  • Increased head size or bulging soft spot (signs of hydrocephalus, or fluid buildup) [5][8].
  • Seizures [5][9].
  • Significant delays in reaching developmental milestones [5].
  • Frequent, unexplained vomiting or extreme irritability [5].

The Risk of Melanoma

Melanoma is a type of skin cancer. Historically, the risk of melanoma for children with GCMN was believed to be as high as 10% or 15%, but modern research shows that the actual lifetime risk is likely lower, often estimated between 2% and 5% [10][11]. While this is still significantly higher than the general population, the majority of children with GCMN will never develop melanoma [12][2].

Where Melanoma Can Start

In the general population, melanoma usually starts on the very top layer of the skin. In children with GCMN, it can behave differently [2]:

  • Deep Tissues: Melanoma can start deep under the surface of the nevus, in the thick layers of the skin or soft tissue [13][14]. This is why doctors may feel for “deep lumps” during an exam rather than just looking at the surface [1].
  • Central Nervous System: If a child has NCM, melanoma can occasionally develop within the brain or spine itself (leptomeningeal melanoma) [2].
  • Satellites: While less common, melanoma can also arise in the smaller satellite nevi [15].

Monitoring and Screening

Because many of these risks are internal, monitoring usually involves more than just skin checks [1].

  • Baseline MRI: Most specialists recommend an MRI of the brain and spine within the first 6 to 12 months of life for babies at high risk [7][16]. This provides a “map” of any pigment cells in the nervous system [17].
  • Physical Exams: Regular visits to a pediatric dermatologist are essential. They will check for changes in the nevus’s texture, color, or the appearance of new, firm nodules [1][18].
  • Neurological Follow-up: If NCM is suspected or confirmed on an MRI, a pediatric neurologist will help monitor your child’s development and neurological health [19].

Previous: Understanding LCMN/GCMN | Next: Medical Imaging and Pathology

Common questions in this guide

What makes a child with a giant congenital nevus high risk for NCM?
Doctors look for specific risk factors, including a projected adult nevus size of over 40 centimeters, having more than 20 smaller satellite nevi at birth, and a nevus located on the head, neck, or spine.
What are the signs and symptoms of neurocutaneous melanocytosis (NCM)?
If extra pigment cells interfere with the central nervous system, symptoms can include an unusually large head size, a bulging soft spot, seizures, severe developmental delays, and frequent unexplained vomiting.
What is the lifetime risk of melanoma for a child with GCMN?
Modern research estimates the lifetime risk of developing melanoma for children with giant congenital melanocytic nevi to be between 2% and 5%. While higher than the general population, the vast majority of children will never develop melanoma.
How is melanoma monitored in children with large nevi?
Because melanoma can start deep under the surface of the nevus rather than on the top layer of skin, pediatric dermatologists will feel for firm, deep lumps during physical exams. Baseline MRIs are also used to check for pigment cells in the brain and spine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my child meet the 'high risk' criteria for NCM based on their nevus size, location, and the number of satellite spots?
  2. 2.If NCM is present on an MRI but my child has no symptoms, how often should we repeat the imaging?
  3. 3.What specific neurological symptoms (like changes in head size or motor skills) should I be watching for at home?
  4. 4.Since melanoma can start deep under the skin, what does a typical monitoring exam look like for a child with GCMN?
  5. 5.How do we differentiate between a benign 'proliferative nodule' and a concerning change that might be melanoma?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Congenital Melanocytic Nevi.

    Nathan S, Smetona J, Naran S, Bauer BS

    Clinics in plastic surgery 2025; (52(2)):259-269 doi:10.1016/j.cps.2024.09.003.

    PMID: 39986887
  2. 2

    Skin-related quality of life in children and adolescents with congenital melanocytic naevi - an analysis of self- and parent reports.

    Neuhaus K, Landolt MA, Theiler M, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(5)):1105-1111 doi:10.1111/jdv.16131.

    PMID: 31803958
  3. 3

    Neurocutaneous melanocytosis (melanosis).

    Ruggieri M, Polizzi A, Catanzaro S, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(10)):2571-2596 doi:10.1007/s00381-020-04770-9.

    PMID: 33048248
  4. 4

    Giant congenital melanocytic nevi.

    Escandón-Pérez S, Landeta-Sa AP, González-Jasso Y, Arenas-Guzmán R

    Boletin medico del Hospital Infantil de Mexico 2019; (76(6)):251-258 doi:10.24875/BMHIM.18000103.

    PMID: 31769436
  5. 5

    Neurocutaneous Melanocytosis-Associated Hydrocephalus: The Memorial Sloan Kettering Experience from 2001 to 2022.

    Rodriguez S, DeIeso-Frechette F, Umeasor C, et al.

    Pediatric blood & cancer 2025; (72(1)):e31434 doi:10.1002/pbc.31434.

    PMID: 39502030
  6. 6

    Neurocutaneous Melanosis in Association With Large Congenital Melanocytic Nevi in Children: A Report of 2 Cases With Clinical, Radiological, and Pathogenetic Evaluation.

    Chen L, Zhai L, Al-Kzayer LFY, et al.

    Frontiers in neurology 2019; (10()):79 doi:10.3389/fneur.2019.00079.

    PMID: 30792691
  7. 7

    Central Nervous System Involvement and Neuroradiological Imaging Insights of Neurocutaneous Melanocytosis in Congenital Melanocytic Nevi.

    Ruff C, Gohla G, Nägele T, Batra M

    Diagnostics (Basel, Switzerland) 2024; (14(21)) doi:10.3390/diagnostics14212345.

    PMID: 39518313
  8. 8

    Neurosurgical management of patients with neurocutaneous melanosis: a systematic review.

    Rahman RK, Majmundar N, Ghani H, et al.

    Neurosurgical focus 2022; (52(5)):E8 doi:10.3171/2022.2.FOCUS21791.

    PMID: 35535823
  9. 9

    Spinal Neurocutaneous Melanosis.

    Demartini Z, Maeda AK, Cardoso-Demartini A

    World neurosurgery 2025; (193()):100-101 doi:10.1016/j.wneu.2024.10.050.

    PMID: 39455004
  10. 10

    Melanoma arising in a Giant congenital melanocytic nevus: two case reports.

    Belysheva TS, Vishnevskaya YV, Nasedkina TV, et al.

    Diagnostic pathology 2019; (14(1)):21 doi:10.1186/s13000-019-0797-1.

    PMID: 30782194
  11. 11

    The outcome of using different surgical modalities and laser therapy in the treatment of small- and medium-sized congenital melanocytic nevi: a systematic review.

    ALMutairi HM, Al-Hothali GI

    International journal of dermatology 2020; (59(5)):535-542 doi:10.1111/ijd.14727.

    PMID: 31792950
  12. 12

    Congenital melanocytic naevi: An up-to-date overview.

    Farabi B, Akay BN, Goldust M, et al.

    The Australasian journal of dermatology 2021; (62(2)):e178-e191 doi:10.1111/ajd.13535.

    PMID: 33591589
  13. 13

    Malignant Melanoma in Association With a Thymic Nevus in a Patient With a Giant Congenital Nevus.

    Shvartser-Beryozkin Y, Yakobson A, Benharroch D, et al.

    The American Journal of dermatopathology 2017; (39(7)):538-541 doi:10.1097/DAD.0000000000000817.

    PMID: 28033154
  14. 14

    Isolated melanoma metastasis in a patient with large congenital nevus without detectable primary melanoma: a case report and review of literature.

    Pabianek M, Jatczak-Grochala I, Lesiak A, et al.

    Frontiers in medicine 2024; (11()):1427982 doi:10.3389/fmed.2024.1427982.

    PMID: 39473498
  15. 15

    Aggressive infantile melanoma arising in a congenital nevus with rare BRAF and BCOR mutations: a case report and literature review of pediatric melanoma.

    Mordechai O, Ofir H, Leitner O, et al.

    Dermatology reports 2026; doi:10.4081/dr.2026.10470.

    PMID: 41645671
  16. 16

    A large-scale collection of giant congenital melanocytic nevi: Clinical and histopathological characteristics.

    Wu M, Yu Q, Gao B, et al.

    Experimental and therapeutic medicine 2020; (19(1)):313-318 doi:10.3892/etm.2019.8198.

    PMID: 31853305
  17. 17

    Congenital melanocytic nevi and risk of melanoma.

    Pastore LM, Valentini R, Marghoob AA

    Clinics in dermatology 2025; (43(3)):378-384 doi:10.1016/j.clindermatol.2024.09.004.

    PMID: 39304091
  18. 18

    Thickness of melanocytes in giant congenital melanocytic nevus for complete surgical excision: clinicopathological evaluation of 117 lesions according to the area and size.

    Kim JY, Lee SY, Kwak Y, Kim BJ

    BMC surgery 2024; (24(1)):90 doi:10.1186/s12893-024-02362-x.

    PMID: 38491443
  19. 19

    Congenital melanocytic nevi.

    Moustafa D, Blundell AR, Hawryluk EB

    Current opinion in pediatrics 2020; (32(4)):491-497 doi:10.1097/MOP.0000000000000924.

    PMID: 32692047

This page explains the medical risks associated with large and giant congenital melanocytic nevi for educational purposes only. Always consult your pediatric dermatologist and neurologist regarding your child's specific monitoring plan.

Get notified when new evidence is published on Large/giant congenital melanocytic nevus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.